Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
grapiprant · 1 trial · 1 indication
Number of incidence, severity, and duration of treatment emergent adverse events using CTCAE v5.0
Number, incidence and severity of treatment related adverse events as assessed by CTCAE 5.0
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Single Agent run-in with grapiprant and then combination treatment of grapiprant and pembrolizumab. |
| Cohort 2 | EXPERIMENTAL | Participants will be treated with grapiprant in combination with pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| grapiprant | DRUG | Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab. |
| grapiprant and pembrolizumab | DRUG | Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab. |
Key Inclusion Criteria: * Male and female adult patients 18 years of age or older on day of signing informed consent. * Patients must have a histologically confirmed advanced, metastatic, or progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC) per institutional standards. * Patient has r...
Grapiprant is an investigational small molecule being studied for the treatment of microsatellite stable colorectal cancer. It is being evaluated in combination with pembrolizumab in patients with advanced or progressive MSS colorectal cancer. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Grapiprant is a small molecule that targets the EP4 receptor, a subtype of the prostaglandin E2 receptor. By inhibiting this receptor, grapiprant may modulate the tumor microenvironment and enhance anti-tumor immune responses. This mechanism is being explored in the context of microsatellite stable colorectal cancer, where it is combined with pembrolizumab.
Grapiprant is being developed by Merck & Company, Inc., a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical research to evaluate grapiprant's safety and efficacy in patients with microsatellite stable colorectal cancer.
Grapiprant is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies for any use. The ongoing research is focused on assessing its safety, tolerability, and preliminary efficacy in patients with advanced or progressive microsatellite stable colorectal cancer.
Grapiprant has been studied in one completed Phase 1 clinical trial, identified as NCT03658772. This trial, titled "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer," enrolled 54 participants in the United States. The study was controlled but not randomized or double-blinded, and it included biomarker-selected patients.
Grapiprant is not known to have alternative names. It is a distinct investigational compound developed by Merck & Company, Inc. In clinical trials, it is being studied as a combination therapy with pembrolizumab, an immune checkpoint inhibitor, for the treatment of microsatellite stable colorectal cancer.